ANTI-TNFA ANTIBODIES WITH PH-DEPENDENT ANTIGEN BINDING

The invention relates to anti-TNFα antibodies which are engineered to exhibit a pH-sensitive antigen binding. The invention is preferably directed to anti-TNFα antibody adalimumab (Humira®) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or...

Full description

Saved in:
Bibliographic Details
Main Authors GUENTHER, Ralf, RHIEL, Laura, HOCK, Bjoern, BECKER, Stefan, SCHROETER, Christian
Format Patent
LanguageEnglish
French
German
Published 08.06.2022
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:The invention relates to anti-TNFα antibodies which are engineered to exhibit a pH-sensitive antigen binding. The invention is preferably directed to anti-TNFα antibody adalimumab (Humira®) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or fragment thereof is engineered by modifications of amino acid sequence within the variable regions. Specifically, the invention relates to adalimumab or biologically active variants or fragments thereof, wherein the CDR domains are modified by replacing one or more amino acid residues by histidine residues.
Bibliography:Application Number: EP20150732165